Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA ISOTOPE & RADIATION CORPORATION
中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT
CIRC'S RADIATION SOURCE R&D AND PRODUCTION BASE SUCCESSFULLY OBTAINS RADIATION SAFETY LICENSE

This announcement is voluntarily made by China Isotope & Radiation Corporation ("**CIRC**" or the "**Company**") to keep its shareholders and potential investors informed of the latest business developments of the Company.

The Board of Directors of the Company is pleased to announce that recently, the radioactive source R&D and production base (the "**Project**") of Sichuan CNNC Tongyuan Technology Co., Ltd.(四川中核同源科技有限公司), a subsidiary of CIRC, has been successfully granted the radiation safety license, officially acquiring the qualifications for the production and sales of radioactive sources, among other related capabilities. The products will be gradually introduced to the market.

The Project is the largest radiation source production base in Asia, comprising 13 production lines for various radioactive sources, including carbon-14 sources and krypton-85 sources. Upon completion, the Project will achieve an annual production capacity of over 100,000 radioactive sources. CIRC will consolidate major domestic R&D and production resources for radioactive sources, offering high-quality radiation source products featuring over 70 nuclides to domestic and international markets. Additionally, the Company will provide services such as radioactive source recycling and irradiation, contributing significantly to the application of radiation technology in fields including industry, agriculture, medicine, national defense, and aerospace in China.

In the future, CIRC will advance the Phase II development of the Project in accordance with high standards, further expanding production capacity and enriching the product portfolio. Plans include the addition of production lines for radioactive sources such as californium-252, cesium-137, and americium-241, aiming to comprehensively meet diverse market demands.

By order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 22 August 2025

As at the date of this announcement, the Board comprises Mr. Xiao Yafei, Mr. Zhang Junqi, Ms. Huo Yingying and Ms. Ma Xiaoyu as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.